View in EDS HTML Full Text PDF Full Text

Bioequivalence of alternative pembrolizumab dosing regimens: current practice and future perspectives.

Saved in:
Bibliographic Details
Title: Bioequivalence of alternative pembrolizumab dosing regimens: current practice and future perspectives.
Authors: Malmberg R; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands., Agema BC; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands., Hofman MM; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.; Department of Pulmonary Medicine, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands., Oosterveld S; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands., Bins S; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands., Dumoulin DW; Department of Pulmonary Medicine, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands., Joosse A; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands., Aerts JGJV; Department of Pulmonary Medicine, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands., Debets R; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands., Koch BCP; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands., van der Veldt AAM; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands., van Leeuwen RWF; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Source: Cancer communications (London, England) [Cancer Commun (Lond)] 2025 Apr; Vol. 45 (4), pp. 471-475. Date of Electronic Publication: 2025 Jan 16.
Publication Type: Journal Article
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101723675 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2523-3548 (Electronic) Linking ISSN: 25233548 NLM ISO Abbreviation: Cancer Commun (Lond) Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39817458
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Bioequivalence of alternative pembrolizumab dosing regimens: current practice and future perspectives.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Malmberg+R%22">Malmberg R</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Agema+BC%22">Agema BC</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Hofman+MM%22">Hofman MM</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.; Department of Pulmonary Medicine, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Oosterveld+S%22">Oosterveld S</searchLink>; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Bins+S%22">Bins S</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Dumoulin+DW%22">Dumoulin DW</searchLink>; Department of Pulmonary Medicine, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Joosse+A%22">Joosse A</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Aerts+JGJV%22">Aerts JGJV</searchLink>; Department of Pulmonary Medicine, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Debets+R%22">Debets R</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Koch+BCP%22">Koch BCP</searchLink>; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Veldt+AAM%22">van der Veldt AAM</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Leeuwen+RWF%22">van Leeuwen RWF</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Mathijssen+RHJ%22">Mathijssen RHJ</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101723675%22">Cancer communications (London, England)</searchLink> [Cancer Commun (Lond)] 2025 Apr; Vol. 45 (4), pp. 471-475. <i>Date of Electronic Publication: </i>2025 Jan 16.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101723675 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2523-3548 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225233548%22">25233548 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Commun (Lond) <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39817458
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/cac2.12661
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 471
    Titles:
      – TitleFull: Bioequivalence of alternative pembrolizumab dosing regimens: current practice and future perspectives.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Malmberg R
      – PersonEntity:
          Name:
            NameFull: Agema BC
      – PersonEntity:
          Name:
            NameFull: Hofman MM
      – PersonEntity:
          Name:
            NameFull: Oosterveld S
      – PersonEntity:
          Name:
            NameFull: Bins S
      – PersonEntity:
          Name:
            NameFull: Dumoulin DW
      – PersonEntity:
          Name:
            NameFull: Joosse A
      – PersonEntity:
          Name:
            NameFull: Aerts JGJV
      – PersonEntity:
          Name:
            NameFull: Debets R
      – PersonEntity:
          Name:
            NameFull: Koch BCP
      – PersonEntity:
          Name:
            NameFull: van der Veldt AAM
      – PersonEntity:
          Name:
            NameFull: van Leeuwen RWF
      – PersonEntity:
          Name:
            NameFull: Mathijssen RHJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2025 Apr
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2523-3548
          Numbering:
            – Type: volume
              Value: 45
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Cancer communications (London, England)
              Type: main
ResultId 1